FIELD: medicine, therapy.
SUBSTANCE: one should apply a polymeric water-soluble analog of acetylsalicylic acid at the dose of 1 mg/kg by acetylsalicylic acid intragastrically. The present innovation decreases blood viscosity and thrombocytic and erythrocytic aggregation.
EFFECT: higher efficiency of prophylaxis.
3 dwg
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR PREVENTING AND TREATING MYOCARDIAL ISCHEMIA | 2002 |
|
RU2241463C2 |
POLYMERIC WATER-SOLUBLE ANALOG OF ACETYL-SALICYLIC ACID AND METHOD OF ITS SYNTHESIS | 2000 |
|
RU2201234C2 |
PHARMACEUTICAL COMPOSITION POSSESSING ANTIAGGREGANT ACTIVITY | 2019 |
|
RU2709017C1 |
COMBINATION POSSESSING ANTIAGGREGANT, LIPID-REGULATING AND GASTROPROTECTIVE ACTIVITIES, PHARMACEUTICAL COMPOSITION | 2010 |
|
RU2453314C1 |
COMBINED ANTIAGGREGANT AND ANTIOXIDANT | 2010 |
|
RU2430728C1 |
AGENT SHOWING ANTIAGGREGANT AND ANTITHROMBOGENIC ACTIVITY | 2010 |
|
RU2453312C1 |
2-(3,4-DIHYDROXYPHENYL)-9-DIETHYLAMINOETHYLIMIDAZO[1,2-a]BENZIMIDAZOLE DIHYDROBROMIDE AND BASED ON IT PHARMACEUTICAL COMPOSITION | 2008 |
|
RU2391979C2 |
METHOD OF SELECTING OPTIMUM DOSE OF ACETYLSALICYLIC ACID IN ARTERIAL THROMBOSIS | 0 |
|
SU1767429A1 |
DICALCIUM SALT OF N-(3-HYDROXYBENZOYL)TAURINE, HAVING ANTIAGGREGANT AND ANTITHROMBOTIC ACTIVITY IN COMBINATION WITH CEREBROPROTECTIVE ACTION | 2019 |
|
RU2730835C1 |
ANTIAGGREGANT | 2005 |
|
RU2353363C2 |
Authors
Dates
2004-12-10—Published
2002-11-22—Filed